Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F Schlenk

Showing results (1-10 of 212) with videos related to

Pageof 22
Sort By:
Haematologica|November 25, 2014
Post-remission therapy for acute myeloid leukemiaRichard F Schlenk
Haematologica|June 4, 2024
Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemiaRichard F Schlenk
Best Practice & Research. Clinical Haematology|November 29, 2016
Is there justification for 4 cycles of consolidation therapy in AML?Richard F Schlenk
Haematologica|February 1, 2023
Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challengesRichard F Schlenk
Hematology. American Society of Hematology. Education Program|December 10, 2013
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemiaRichard F Schlenk, Hartmut Döhner
Expert Opinion on Biological Therapy|May 29, 2014
Gemtuzumab ozogamicin in acute myeloid leukemia revisitedFelicitas Thol, Richard F Schlenk
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic MastocytosisRichard F Schlenk, Sabine Kayser
Haematologica|February 1, 2023
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the questionSonia Jaramillo, Richard F Schlenk
Haematologica|January 15, 2026
All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PROSabine Kayser, Richard F Schlenk
Current Opinion in Hematology|May 27, 2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemiaRichard F Schlenk, Konstanze Döhner
Pageof 22

Showing results (1-10 of 212) with videos related to

Sort By:
Pageof 22
Haematologica|November 25, 2014
Post-remission therapy for acute myeloid leukemiaRichard F Schlenk
Haematologica|June 4, 2024
Genetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemiaRichard F Schlenk
Best Practice & Research. Clinical Haematology|November 29, 2016
Is there justification for 4 cycles of consolidation therapy in AML?Richard F Schlenk
Haematologica|February 1, 2023
Acute myeloid leukemia: introduction to a series highlighting progress and ongoing challengesRichard F Schlenk
Hematology. American Society of Hematology. Education Program|December 10, 2013
Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemiaRichard F Schlenk, Hartmut Döhner
Expert Opinion on Biological Therapy|May 29, 2014
Gemtuzumab ozogamicin in acute myeloid leukemia revisitedFelicitas Thol, Richard F Schlenk
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic MastocytosisRichard F Schlenk, Sabine Kayser
Haematologica|February 1, 2023
Update on current treatments for adult acute myeloid leukemia: to treat acute myeloid leukemia intensively or non-intensively? That is the questionSonia Jaramillo, Richard F Schlenk
Haematologica|January 15, 2026
All patients with AML and FLT3-ITD should be transplanted in first remission. Also in the era of tyrosine kinase inhibitors? - the PROSabine Kayser, Richard F Schlenk
Current Opinion in Hematology|May 27, 2009
Impact of new prognostic markers in treatment decisions in acute myeloid leukemiaRichard F Schlenk, Konstanze Döhner
Pageof 22